The role of inflammatory cytokines in diabetic nephropathy

Journal of the American Society of Nephrology

Volumn 19, Issue 3, 2008, Pages 433-442

  Navarro González, Juan F ^a,b   Mora Fernández, Carmen ^a  

^a HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENETICS; IMMUNE SYSTEM; IMMUNITY; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY;

EID: 40449113524     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2007091048     Document Type: Short Survey

References (134)

1. Beaglehole R, Yach D: Globalisation and the prevention and control of non-communicable disease: The neglected chronic disease of adults. Lancet 362: 1763-1764, 2003
2. Yach D, Hawkes C, Gould C, Hofman K: The global burden of chronic diseases: Overcoming impediments to prevention and control. JAMA 291: 2616-2622, 2004
3. Ritz E, Rychlik I, Locatelli F, Halimi S: End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 34: 795-808, 1999
4. Williams MD, Nadler JL: Inflammatory mechanisms of diabetic complications. Curr Diab Rep 7: 242-248, 2007
5. Navarro JF, Mora C: Role of inflammation in diabetic complications. Nephrol Dial Transplant 20: 2601-2604, 2005
6. Turtle KR: Linking metabolism and immunology: Diabetic nephropathy is an inflammatory disease. J Am Soc Nephrol 16: 1537-1538, 2005
7. Mora C, Navarro JF: Inflammation and diabetic nephropathy. Curr Diabetes Rep 6: 463-468, 2006
8. Galkina E, Ley K: Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol 17: 368-377, 2006
9. Shikata K, Makino H: Role of macrophages in the pathogenesis of diabetic nephropathy. Contrib Nephrol 1: 46-54, 2001
10. Chow F, Ozols E, Nikolic-Paterson DJ, Atkins R, Tesch G: Macrophages in mouse type 2 diabetic nephropathy: Correlation with diabetic state and progressive renal injury. Kidney Int 65: 116-128, 2004
11. Ihm CG: Monocyte chemotactic peptide-1 in diabetic nephropathy. Kidney Int Suppl 60: S20-S22, 1997
12. Chow F, Nikolic-Paterson DJ, Ozols E, Atkins R, Rollin BJ, Tesch G: Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 69: 73-80, 2006
13. Okada S, Shikata K, Matsuda M, Ogawa D, Usui H, Kido Y, Nagase R, Wada J, Shikata Y, Makino H: Intercellular adhesion molecule-1 deficient mice are resistant against renal injury after induction of diabetes. Diabetes 52: 2586-2593, 2003
14. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins R, Tesch G: Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J Am Soc Nephrol 16: 1711-1722, 2005
15. Cheng H, Wang C, Moeckel G, Zhang M, Mckanna J, Harris R: Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int 62: 929-939, 2002
16. Komers R, Lindsley J, Oyama TT, Anderson S: Cyclo-oxygenase-2 inhibition attenuates the progression of nephropathy in uninephrectomized diabetic rats. Clin Exp Pharmacol Physiol 34: 36-41, 2007
17. Levine DZ: Hyperfiltration, nitric oxide, and diabetic nephropathy. Curr Hypertens Rep 8: 153-157, 2006
18. Quaggin SE, Coffman TM: Toward a mouse model of diabetic nephropathy: Is endothelial nitric oxide synthase the missing link? J Am Soc Nephrol 18: 364-366, 2007
19. Nakagawa T: Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. Am J Physiol Renal Physiol 292: F1665-F1672, 2007
20. Flyvbjerg A, Khatir DS, Jensen LJ, Dagnaes-Hansen F, Gronbaek H, Rasch R: The involvement of growth hormone (GH), insulin-like growth factors (IGFs) and vascular endothelial growth factor (VEGF) in diabetic kidney disease. Curr Pharm Des 10: 3385-3394, 2004
21. Pantsulaia T: Role of TGF-beta in pathogenesis of diabetic nephropathy. Georgian Med News 131: 13-18, 2006
22. Schena FP, Gesualdo L: Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol 16[Suppl 1]: S30-S33, 2005
23. Mezzano S, Aros C, Droguet A, Burgos ME, Ardiles L, Flores C, Schneider H, Ruiz-Ortega M, Egido J: NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 19: 2505-2512, 2004
24. Schmid H, Boucherot A, Yasuda Y, Henger A, Brunner B, Eichinger F, Nitsche A, Kiss E, Bleich M, Grone HJ, Nelson PJ, Schlondorff D, Cohen CD, Kretzler M; European cDNA Bank (ERCB) Consortium: Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 2006 55: 2993-3003, 2006
25. Coppack SW: Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 60: 349-356, 2001
26. AldhahiW, Hamdy O: Adipokines, inflammation, and the endothelium in diabetes. Curr Diab Rep 3: 293-298, 2003
27. Balwilk FR, Burke F: The cytokine network. Immunol Today 10: 299-304, 1989
28. Pickup J, Crook M: Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41: 1241-1248, 1998
29. Crook M: Type 2 diabetes mellitus: A disease of the innate immune system? An update. Diabet Med 21: 203-207, 2004
30. Pickup JC: Inflammation and activated innate immune system in the pathogenesis of type 2 diabetes. Diabetes Care 27: 813-823, 2004
31. Bloomgarden ZT: Inflammation and insulin resistance. Diabetes Care 26: 1922-1926, 2003
32. Dandona P, Aljada A, Bandyopadhyay A: Inflammation: The link between insulin resistance, obesity and diabetes. Trends Immunol 25: 4-7, 2004
33. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage P, Offenbacher S, Azambuja M, Tracy R, Heiss G: Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities Study): A cohort study. Lancet 353: 1649-1652, 1999
34. Pradhan AD, Manson JE, Rifai N, Buring J, Ridker P: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286: 327-334, 2001
35. Spranger J, Kroke A, Möhlig M, Hoffmann K, Bergmann M, Ristow M, Boeing H, Pfeiffer A: Inflammatory cytokines and the risk to develop type 2 diabetes: Results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC) Potsdam study. Diabetes 52: 812-817, 2003
36. Alexandraki K, Piperi C, Kalofoutis C, Singh J, Alaveras A, Kalofoutis A: The inflammatory process in type 2 diabetes. The role of cytokines. Ann N Y Acad Sci 1084: 89-117, 2006
37. Skundric DS, Lisak RP: Role of neuropoietic cytokines in development and progression of diabetic polyneuropathy: From glucose metabolism to neurodegeneration. Exp Diabesity Res 4: 303-312, 2003
38. Jeffcoate WJ, Game F, Cavanagh PR: The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet 336: 2058-2061, 2005
39. Mocan MC, Kadayifcilar S, Eldem B: Elevated intravitreal interleukin-6 levels in patients with proliferative diabetic retinopathy. Can J Ophthalmol 41: 747-752, 2006
40. Determinations of vitreous interleukin-1 (IL-1) and tumor necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye 20: 1366-1369, 2006
41. Vilcek J: The cytokines: An overview. In: The Cytokine Handbook, 4th Ed., edited by Thomson AW, Lotze MT, Academic Press, London, 2003, pp 3-18
42. Hasegawa G, Nakano K, Sawada M, Uno K, Shibayama Y, Ienaga K, Kondo M: Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 40: 1007-1012, 1991
43. Hasegawa G, Nakano K, Kondo M: Role of TNF and IL-1 in the development of diabetic nephropathy. Nefrologia 15: 1-4, 1995
44. Sassy-Prigent C, Heudes D, Jouquey S, Auberval D, Belair MF, Michel O, Hamon G, Bariety J, Bruneval P: Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes 49: 466-475, 2000
45. Navarro JF, Milena FJ, Mora C, Leon C, Garcia J: Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: Effect of angiotensin- converting enzyme inhibition and pentoxifylline administration. Am J Nephrol 26: 562-570, 2006
46. Brady HR: Leukocyte adhesion molecules and kidney diseases. Kidney Int 45: 1285-1300, 1994
47. Park CW, Kim JH, Lee JH, Kim YS, Ahn HJ, Shin YS, Kim SY, Choi EJ, Chang YS, Bang BK: High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NFkapa B-dependent. Diabe tologia 43: 1544-1553, 2000
48. Pfeilschifter J, Pignat W, Vosbeck K, Märki F: Interleukin 1 and tumor necrosis factor synergistically stimulate prostaglandin synthesis and phospholipase A2 release from rat renal mesangial cells. Biochem Biophys Res Commun 159: 385-394, 1989
49. Pfeilschifter J, Muhl H: Interleukin-1 and tumor necrosis factor potentiate angiotensin II- and calcium ionophore-stimulated prostaglandin E2 synthesis in rat renal mesangial cells. Biochem Biophys Res Com mun 169: 585-595, 1990
50. Royall JA, Berkow RL, Beckman JS, Cunningham MK, Matalon S, Freeman BA: Tumor necrosis factor and interleukin 1 increase vascular endothelial permeability. Am J Physiol 257: L339-L410, 1989
51. Jones S, Jones S, Phillips AO: Regulation of renal proximal tubular epithelial cell hyaluronan generation: implications for diabetic nephropathy. Kidney Int 59: 1739-1749, 2001
52. Mahadevan P, Larkins RG, Fraser JR, Fosang AJ, Dunlop ME: Increased hyaluronan production in the glomeruli from diabetic rats: Link between glucose induced prostaglandin production and reduced sulphated proteoglycans. Diabetologia 38: 298-305, 1995
53. Sekizuka K, Tomino Y, Sei C, Kurusu A, Tashiro K, Yamaguchi Y, Kodera S, Hishiki T, Shirato I, Koide H: Detection of serum IL-6 in patients with diabetic nephropathy. Nephron 68: 284-285, 1994
54. Suzuki D, Miyazaki M, Naka R, Koji T, Yagame M, Endoh M, Sakai H: In situ hybridization of interleukin 6 in diabetic nephropathy. Diabetes 44: 1233-1238, 1995
55. Nosadini R, Velussi M, Brocco E, Bruseghin M, Abaterusso C, Saller A, Dalla Vestra M, Carraro A, Bortoloso E, Sambataro M, Barzon I, Frigato F, Muollo B, Chiesura-Corona M, Pacini G, Baggio B, Piarulli F, Sfriso A, Fioretto P: Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate. Diabetes 49: 476-484, 2000
56. Dalla Vestra M, Mussap M, Gallina P, Brueghin M, Cernigoi AM, Saller A, Plebani M, Fioretto P: Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol 16 [Suppl 1]: S78-S82, 2005
57. Thomson SC, Deng A, Bao D, Satriano J, Blantz RC, Vallon V: Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes. J Clin Invest 107: 217-224, 2001
58. Hirano T, Akira S, Taga T, Kishimoto T: Biological and clinical aspects of interleukin 6. Immunol Today 11: 443-449, 1990
59. Ruef C, Budde K, Lacy J, Northemann W, Baumann M, Sterzel RB, Coleman DL: Interleukin 6 is an autocrine growth factor for mesangial cells. Kidney Int 38: 249-257, 1990
60. Coleman DL, Ruef C: Interleukin-6: an autocrine regulator of mesangial cell growth. Kidney Int 41: 604-606, 1992
61. Okamura H, Tsutsui H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K, Akita K, Namba M, Tanabe F, Konishi K, Fukuda S, Kurimoto M: Cloning a new cytokine that induces IFN-production by T cells. Nature 378: 88-91, 1995
62. Schwartz M, Wahl M, Resch K, Radeke HH: IFNgamma induces functional chemokine receptor expression in human mesangial cells. Clin Exp Immunol 128: 285-294, 2002
63. Dai SM, Matsuno H, Nakamura H, Nishioka K, Yudoh K: Interleukin-18 enhances monocyte tumor necrosis factor alpha and interleukin-1 beta production induced by directo contact with T lymphocytes: implications in rheumatoid arthritis. Arthritis Rheum 50: 432-443, 2004
64. Marino E, Cardier JE: Differential effects of IL-18 on endothelial cell apoptosis mediated by TNF-alpha and Fas (CD59). Cyto kine 22: 142-148, 2003
65. Stuyt RJ, Netea MG, Geijtenbeek TB, Kullberg BJ, Dinarello CA, van der Meer JW: Selective regulation of intercellular adhesion molecule-1 expression by interleukin-18 and interleukin-12 on human monocytes. Immunology 110: 329-334, 2003
66. Fantuzzi G, Reed DA, Dinarello CA: IL-12-induced IFN-gamma is dependent of caspase-1 processing of the IL-18 precursor. J Clin Invest 104: 761-767, 1999
67. Melnikov VY, Ecder T, Fantuzzi G, Siegmund B, Lucia MS, Dinarello CA, Schrier RW, Edelstein CL: Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. J Clin Invest 107: 1145-1152, 2001
68. Melnikov VY, Faubel S, Siegmund B, Lucia MS, Ljubanovic D, Edelstein CL: Neutrophil-independent mechanisms of caspase-1 and IL-18 mediated ischemic acute tubular necrosis in mice. J Clin Invest 110: 1083-1091, 2002
69. Moriwaki Y, Yamamoto T, Shibutani Y, Aoki E, Tsutsumi Z, Takahashi S, Okamura H, Koga M, Fukuchi M, Hada T: Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism 52: 605-608, 2003
70. Nakamura A, Shikata K, Hiramatsu M, Nakatou T, Kitamura T, Wada J, Itoshima T, Makino H: Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care 28: 2890-2895, 2005
71. Wong CK, Ho AWY, Tong PCY, Yeung CY, Kong APS, Lun SWM, Chan JCN, Lam CWK: Aberrant activation profile of cytokines and mitogen-activated protein kinases in type 2 diabetic patients with nephropathy.
72. Jevnikar AM, Brennan DC, Singer GG, Heng JE, Maslinski W, Wuthrich RP, Glimcher LH, Kelley VE: Stimulated kidney tubular epithelial cells express membrane associated and secreted TNF alpha. Kidney Int 40: 203-211, 1991
73. Nakamura T, Fukui M, Ebihara I, Osada S, Nagaoka I, Tomino Y, Koide H: mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 42: 450-456, 1993
74. Sugimoto H, Shikata K, Wada J, Horiuchi S, Makino H: Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: Aminoguanidine ameliorates the overexpression of tumour necrosis factor-alpha and inducible oxide synthase in diabetic rat glomerli. Diabetologia 42: 878-886, 1999
75. Dong X, Swaminathan S, Bachman LA, Croatt AJ, Nath KA, Griffin MD: Resident dendritic cells are the predominant TNF-secreting cell in early renal ischemia-reperfusion injury. Kidney Int 71: 619-628, 2007
76. Zhang B, Ramesh G, Norbury CC, Reeves WB: Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. Kid ney Int 72: 37-44, 2007
77. Wang X, Feuerstein GZ, Xu L, Wang H, Schumacher WA, Ogletree ML, Taub R, Duan JJ, Decicco CP, Liu RQ: Inhibition of tumor necrosis factor-alpha- converting enzyme by a selective antagonist protects brain from focal ischemic injury in rats. Mol Pharamcol 65: 890-896, 2004
78. Ortiz A, Bustos C, Alonso J, Alcazar R, Lopez-Armada MJ, Plaza JJ, Gonzalez E, Egido J: Involvement of tumor necrosis factor-alpha in the pathogenesis of experimental, and human glomerulonephritis. Adv Nephrol Necker Hosp 24: 53-77, 1995
79. Bertani T, Abbate M, Zoja C, Coma D, Perico N, Ghezzi P, Remuzzi G: Tumor necrosis factor induces glomerular damage in rabbit. Am J Pathol 134: 419-430, 1989
80. Laster SM, Wood JG, Gooding LR: Tumor necrosis factor can induce both apoptotic and necrotic forms of cell lysis. J Immunol 141: 2629-2634, 1988
81. Boyle JJ, Weissberg PL, Bennett MR: Tumor necrosis factor-alpha promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms. Arterioscler Thromb Vasc Biol 23: 1553-1558, 2003
82. Baud L, Perez J, Friedlander G, Ardaillou R: Tumor necrosis factor stimulates prostaglandin production and cyclic AMP levels in rat cultured mesangial cells. FEBS Lett 239: 50-54, 1998
83. Wojciak-Stothard B, Entwistle A, Garg R, and Ridley AJ: Regulation of TNF-alpha-induced reorganization of the actin cytoskeleton and cell-cell junctions by Rho, Rac, and Cdc42 in human endothelial cells. J Cell Physiol 176: 150-165, 1998
84. Raedke HH, Meier B, Topley N, Fluge J, Habermehl GG, Resch K: Interleukin 1-alpha and tumor necrosis factor-alpha induce oxygen radical production in mesangial cells. Kidney Int 37: 767-775, 1990
85. Koike N, Takamura T, Kaneko S: Induction of reactive oxygen species from isolated rat glomeruli by protein kinase C activation and TNF-α stimulation, and effects of a phosphodiesterase inhibitor. Life Sci 80: 1721-1728, 2007
86. MaCarthy E, Sharma R, Sharma M, Li JZ, Ge XL, Dileepan KN, Savin VJ: TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J Am Soc Nephrol 9: 433-438, 1998
87. Navarro J, Milena F, Mora C, Leon C, Claverie F, Flores C, Garcia J: Tumor necrosis factor-alpha gene expression in diabetic nephropathy: Relatioship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. Kidney Int Suppl 99: S98-S102, 2005
88. Dipetrillo K, Coutermarsh B, Gesek FA: Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. Am J Physiol Renal Physiol 284: F113-F121, 2003
89. DiPetrillo K, Gesek FA: Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats. Am J Nephrol 24: 352-359, 2004
90. Schreiner GF, Kohan DE: Regulation of renal transport processes and hemodynamics by macrophages and lymphocytes. Am J Physiol 258: F761-F767, 1990
91. Kalantarinia K, Awas AS, Siragy HM: Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. Kidney Int 64: 1208-1213, 2003
92. Navarro JF, Mora C, Macía M, García J: Inflammatory parameters are independently associated with urinary albumin excretion in type 2 diabetes mellitus. Am J Kidney Dis 42: 53-61, 2003
93. Navarro JF, Mora C, Muros M, García J: Urinary tumor necrosis factor-alpha is independently associated with clinical markers of renal injury in diabetic patients. Nephrol Dial Transplant 21: 3428-3434, 2006
94. Rich SS: Genetics of diabetes and its complications. J Am Soc Nephrol 17: 353-360, 2006
95. Fioretto P, Steffes MW, Barboso J, Rich SS, Miller ME, Mauer M: Is diabetic nephropathy inherited? Studies of glomerular structure in type 1 diabetic sibling pairs. Diabetes 48: 865-869, 1999
96. Langefeld CD, Beck SR, Bowden DW, Rich SS, Wagenknecht LE, Freedman BI: Heritability of GFR and albuminuria in Caucasians with type 2 diabetes mellitus. Am J Kidney Dis 5: 796-800, 2004
97. Seaquist ER, Goetz FC, Rich SS, Barbosa J: Familial clustering of diabetic kidney disease: Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 320: 1161-1165, 1989
98. Bowden DW: Genetics of diabetes complications. Curr DiabRep 2: 191-200, 2002
99. Placha G, Canani LH, Warram JH, Krolewski AS: Evidence for different susceptibility genes for proteinuria and ESRD in type 2 diabetes. Adv Chronic Kidney Dis 12: 155-169, 2005
100. Hollegaard MV, Bidwell JL: Cytokine gene polymorphism in human disease: on-line databases, Supplement 3. Genes Immun 7: 269-276, 2006
101. Lee SH, Lee TW, Ihm CG, Kim MJ, Woo JT, Chung JH: Genetics of diabetic nephropathy in type 2 DM: Candidate gene analysis for the pathogenic role of inflammation. Nephrology (Carlton) 10[Suppl]: S32-S36, 2005
102. Blakemore AI, Cox A, Gonzalez AM, Maskil JK, Hughes ME, Wilson RM, Ward JD, Duff GW: Interleukin-1 receptor antagonist allele (IL1RN*2) associated with nephropathy in diabetes mellitus. Hum Genet 97: 369-374, 1996
103. Loughrey BV, Maxwell AP, Fogarty DG, Middleton D, Harron JC, Patterson CC, Darke C, Savage DA: An interleukin 1B allele, which correlates with a high secretor phenotype, is associated with diabetic nephropathy. Cytokine 10: 984-988, 1998
104. Lee SH, Ihm CG, Sohn SD, Lee TW, Kim MJ, Koh G, Oh SJ, Woo JT, Kim SW, Kim JW, Kim YS, Lee BC, Kim SD, Cho BS, Lee HJ, Chung JH: Polymorphisms in interleukin-1 beta and interleukin-1 receptor antagonist genes are associated with kidney failure in Korean patients with type 2 diabetes mellitus. Am J Nephrol 24: 410-414, 2004
105. Kitamura A, Hasegawa G, Obayaxhi H, Kamiuchi K, Ishii M, Yano M, Tanaka T, Yamaguchi M, Shigeta H, Ogata M, Nakamura M, Yoshikawa T: Interleukin-6 polymorhpism (-634 C/G) in the promoter region and the progression of diabetic nephropathy in type 2 diabetes. Diabetic Med 19: 1000-1005, 2002
106. Wang H, Zhang Z, Chu W, Hale T, Cooper JJ, Elbein SC: Molecular screening and association analyses of the interleukin-6 receptor gene variants with type 2 diabetes, diabetic nephropathy, and insulin sensitivity. J Clin Endocrinol Metab 90: 1123-1129, 2005
107. Wolford JK, Colligan PB, Gruber JD, Bogardus C: Variants in the interleukin 6 receptor gene are associated with obesity in Pima Indians. Mol Gent Metab 80: 338-343, 2003
108. Kim LH, Lee HS, Kim YJ, Jung JH, Kim JY, Park BL, Shin HD: Identification of novel SNPs in the interleukin 6 receptor gene (IL6R). Human Mutat 21: 450-451, 2003
109. Rao M, Wong C, Kanetsky P, Girndt M, Stenvinkel P, Reilly M, Raj DSC: Cytokine gene polymorphism and progression of renal and cardiovascular diseases. Kidney Int 72: 549-556, 2007
110. Hostetter TH: Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 345: 910-912, 2001
111. Williams ME, Tuttle K: The next generation of diabetic nephropathy therapies: An update. Adv Chronic Kidney Dis 12: 212-222, 2005
112. Dagenais NJ, Jamali F: Protective effects of angiotensin II interruption: Evidence for anti-inflammatory actions. Pharmacotherapy 25: 1213-1229, 2005
113. Dandona P, Dhindsa S, Ghanim H, Chaudhuri A: Angiotensin II and inflammation: The effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Human Hypertens 21: 20-27, 2007
114. Han SY, Kim CH, Kim HS, Jee YH, Song HK, Lee HK, Han KH, Kim HK, Kang YS, Han YS, Kim YS, Cha DR: Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 17: 1362-1372, 2006
115. Takebayashi K, Matsumoto S, Aso Y, Inukai T: Aldosterone blockade attenuates urinary chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metab 91: 2214-2217, 2006
116. Fukami K, Cooper ME, Forbes JM: Agents in development for the treatment of diabetic nephropathy. Expert Opin Investig Drugs 14: 279-294, 2005
117. Bruno S, Cattaneo D, Perico N, Remuzzi G: Emerging drugs for diabetic nephropathy. Expert Opin Investig Drugs 14: 747-771, 2005
118. Utimura R, Fujihara CK, Mattar AL, Costa-Malheiros DMA, Noronha IL, Zatz R: Mycophenolate mophetil prevents the development of glomerular injury in experimental diabetes. Kidney Int 63: 209-216, 2003
119. Moriwaki Y, Inokuchi T, Yamamoto A, Ka T, Tsutsumi Z, Takahashi S, Yamamoto T: Effect of TNF-alpha inhibition on urinary albumin excretion in experimental diabetic rats. Acta Diabetol 44: 215-218, 2007
120. Han J, Thompson P, Beutler D: Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signalling pathway. J Exp Med 172: 393-394, 1990
121. Doherty GM, Jensen JC, Alexander HR, Buresh CM, Norton JA: Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 110: 192-198, 1991
122. Voisin L, Breuille D, Ruot B, Ralliere C, Rambourdin F, Dalle M, Obled C: Cytokine modulation by PX differently affects specific acute phase proteins during sepsis in rats. Am J Physiol Regul Integr Comp Physiol 275: 1412-1419, 1998
123. Tissi L, Puliti M, Barluzzi R, Orefici G, Von Hunolstein C, Bistoni F: Role of tumor necrosis factor alpha, interleukin-1beta, and interleukin-6 in a mouse model of group B streptococcal arthritis. Infect Immun 67: 4545-4550, 1999
124. Cooper A, Mikhail A, Lethbridge LW, Kemeny DM, Macdougall IC: Pentoxifylline improves hemoglobin levels in patients with erythropoietin- resistant anemia in renal failure. J Am Soc Nephrol 15: 1877-1882, 2004
125. Segal R, Dayan M, Zinger H, Mozes E: Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNFalpha monoclonal antibody and by pentoxifillyne. Lupus 10: 23-31, 2001
126. Chen YM, Ng YY, Lin SL, Chiang WC, Lan HY, Tsai TJ: Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats. Nephrol Dial Transplant 19: 1106-1115, 2004
127. Guerrero-Romero F, Rodríguez-Morán M, Paniagua-Sierra J, García-Bulnes G, Salas-Ramírez M, Amato D: Pentoxifylline reduces proteinuria in insulin-dependent and non-dependent diabetic patients. Clin Nephrol 43: 116-121, 1995
128. Navarro JF, Mora C, Rivero A, Gallego E, Chahin J, Macía M, Mendez ML, García J: Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: Effects of pentoxifylline administration. Am J Kidney Dis 33: 458-463, 1999
129. Navarro J, Mora C, Muros M, Macía M, García J: Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: A short-term, prospective, randomised study. Am J Kidney Dis 42: 264-270, 2003
130. Rodríguez-Moran M, Gonzalez-Gonzalez G, Bermúdez-Barba MV, Medina de la Garza CE, Tamez-Perez HE, Martínez-Martínez FJ, Guerrero-Romero F: Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: A double-blind, placebo-controlled randomized trial. Clin Nephrol 66: 3-10, 2006
131. Aminorroaya A, Janghorbani M, Rezvanian H, Aminian T, Gharavi M, Amini M: Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus. Nephron Clin Pract 99: 73-77, 2005
132. Rodríguez-Moran M, Guerrero-Romero F: Pentoxifylline is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients. A randomized, equivalent trial. Clin Nephrol 64: 91-97, 2005
133. Harmankaya O, Seber S, Yilmaz M: Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients. Ren Fail 25: 465-470, 2003
134. Navarro JF, Mora C, Muros M, García J: Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: A short-term, randomised, controlled trial. J Am Soc Nephrol 16: 2119-2126, 2005